China Stories: Brand-Name Drugs Feel the Squeeze in China’s Generic-Heavy Market

Multinational pharmaceutical firms are changing strategies and selling business lines, as a government bulk-buying program favors cheaper, local products. Click here to read the Caixin Global article. Subscribe to a bundle deal now to unlock all coverage by Caixin Global and The Wall Street Journal for only $250 a year. It’s a 60% discount.